Dr Nirmala Chandralega-Kampan
Interleukin-6 (IL-6) in ascites fluid can increase the proportion of TNFR2+ T-regulatory cells (Tregs), to inhibit the activity of anti-tumour T-effector cells (Teffs) and promote immune suppression. Blockade of IL-6 signalling decreased immune suppression, decreased the expression of several checkpoint inhibitor molecules, and increased Teff activity.
Centre for Cancer Research
Ovarian Cancer Biomarkers
Journal and article title
Immune-suppressive TNFR2+ Tregs can arise de novo through the influence of IL6, rather than migrating into the tumour environment as previously hypothesized. These TNFR2+ Tregs have potent immunosuppressive activity, and inhibit TNFR2+ T effector cells to enhance immune suppression in ovarian cancers.
The use of therapies to antagonize IL-6 signalling can stimulate anti-tumour immunity through a reduction in Treg abundance, whilst simultaneously increasing T effector cell function. This could lead to novel adjunct therapies for patients.